Latest On Sonoma Pharmaceuticals, Inc (SNOA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-15 02:42 EST | News | Sonoma Pharmaceuticals GAAP EPS of -$0.62, revenue of $2.94M | N/A |  |
| 2023-01-31 20:19 EST | News | Sonoma stock surges ~15% on distribution pact with Daewoong in South Korea | N/A | |
| 2023-01-25 22:18 EST | News | Sonoma stock soars ~90% on product registration enabling sale to US government | N/A | |
| 2022-11-15 07:59 EST | News | Sonoma Pharmaceuticals GAAP EPS of -$0.33, revenue of $3.3M | N/A | |
| 2022-11-02 23:19 EST | News | AMD, JD and BILI are among pre market gainers | N/A | |
| 2022-08-12 08:06 EST | News | Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M | N/A | |
| 2022-07-13 21:16 EST | News | Sonoma Pharmaceuticals GAAP EPS of -$0.95, revenue of $2.3M | N/A | |
| 2022-06-01 20:56 EST | News | Sonoma gains on new U.S. EPA designation for disinfectant | N/A | |
| 2022-05-03 20:42 EST | News | Sonoma stock soars 21% on EPA approval of Nanocyn as hospital-grade disinfectant | N/A | |
| 2022-03-31 00:10 EST | News | Sonoma Pharma rises 22% on UTI product launch in New Zealand, Australia and South Africa | N/A | |
| 2022-02-12 04:39 EST | News | Sonoma Pharmaceuticals GAAP EPS of -$0.31, revenue of $2.9M | N/A | |
| 2021-11-15 12:56 EST | News | Sonoma Pharmaceuticals reports Q2 results | N/A | |
| 2021-10-15 20:49 EST | News | Sonoma Pharma gains with extended approval for Nanocyn in Australia | N/A | |
| 2021-09-29 00:44 EST | News | Sonoma Pharma gains nearly two-third on product launch in U.S. and Europe | N/A | |
| 2021-08-19 14:21 EST | News | Sonoma Pharma stock jumps 61% on launch of new dental products | N/A | |
| 2021-08-17 01:00 EST | News | Sonoma Pharmaceuticals reports Q1 results | N/A | |
| 2021-04-01 04:07 EST | News | Sonoma shares rise after EMC Pharma tie up | N/A | |
| 2021-02-18 12:23 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-17 09:35 EST | News | Sonoma Pharmaceuticals reports FQ3 results | N/A | |
| 2021-01-29 06:52 EST | News | Sonoma's Dermodacyn disinfectant now available in Thailand after import clearance | N/A | |
| 2020-12-18 00:08 EST | News | Sonoma Pharmaceuticals rallies after hours on partnership with Gabriel Science | N/A | |
| 2020-12-10 18:34 EST | News | Sonoma Pharma +35% on Crown Laboratories partnership | N/A | |
| 2020-11-26 21:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-21 12:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-21 05:10 EST | News | Sonoma Pharmaceuticals reports FQ2 results | N/A | |
| 2020-11-08 00:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-18 17:34 EST | News | Health Canada Ok's Sonoma's disinfectant & sanitizer | N/A | |
| 2020-09-17 06:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-11 11:08 EST | News | Sonoma Pharma +8% on launch of two new products in Australia | N/A | |
| 2020-08-16 01:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-15 05:19 EST | News | Sonoma Pharmaceuticals reports FQ1 results | N/A | |
| 2020-08-14 10:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 13:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 17:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 04:49 EST | News | Sonoma Pharma up big on potential of disinfectant/sanitizer in airline industry | N/A | |
| 2020-07-27 13:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 18:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-12 18:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-10 22:49 EST | News | Sonoma Pharmaceuticals reports Q4 results | N/A | |
| 2020-07-09 10:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 17:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 13:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 05:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 06:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-29 19:40 EST | News | Sonoma Pharma up big on COVID-19 nod in Australia for disinfectant | N/A | |
| 2020-05-27 06:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 01:51 EST | Financials | Company financials have been released. | Neutral | |
About Sonoma Pharmaceuticals, Inc (SNOA):
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
General
- Name Sonoma Pharmaceuticals, Inc
- Symbol SNOA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 19
- Last Split Factor1:9
- Last Split Date2019-06-20
- Fiscal Year EndMarch
- IPO Date2007-01-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.sonomapharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 0.68
- Price/Book (Most Recent Quarter) 1.31
- Enterprise Value Revenue 0.57
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -8%
- Operating Margin -14%
- Return on Assets -11%
- Return on Equity -20%
- Revenue 21.79 million
- Earnings Per Share -$7.06
- Revenue Per Share $11.36
- Gross Profit 8.33 million
- Quarterly Earnings Growth 12.3%
View More
Highlights
- Market Capitalization 16.07 million
- EBITDA -8147000
- Analyst Target Price $9
- Book Value Per Share $5.92
View More
Share Statistics
- Shares Outstanding 2.08 million
- Shares Float 2.05 million
- % Held by Insiders 107%
- % Held by Institutions 9.49%
- Shares Short 3893
- Shares Short Prior Month 19223
- Short Ratio 0.05
View More
Technicals
- Beta 0.79
- 52 Week High $10.09
- 52 Week Low $4.28
- 50 Day Moving Average 8.33
- 200 Day Moving Average 7.87
View More
Dividends
- Dividend Date 2019-06-20
- ExDividend Date N/A
- Dividend Yield 0%
View More
Sonoma Pharmaceuticals, Inc (SNOA) Dividend Calendar:
SNOA's last dividend payment was made to shareholders on June 20, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Sonoma Pharmaceuticals, Inc (SNOA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-17 | $4.94 million | -$0.32 | ||
| 2020-09-30 | 2020-12-31 | $5.77 million | -$0.31 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $0.07 | ||
| 2020-03-31 | 2020-06-30 | $N/A | -$0.39 | ||
| 2019-12-31 | 2020-03-31 | $4.68 million | -$0.77 | ||
| 2019-09-30 | 2019-12-31 | $4.97 million | -$0.81 | -$1.18 | 31.64% |
| 2019-06-30 | 2019-07-01 | $4.71 million | -$2.45 | -$2.45 | 0% |
| 2019-03-31 | 2019-06-30 | $4.38 million | -$1.52 | -$2.12 | 28.3% |
| 2018-12-31 | 2019-02-14 | $5.28 million | -$2.34 | -$3.02 | 22.39% |
| 2018-09-30 | 2018-11-08 | $4.94 million | -$3.96 | -$4.10 | 3.3% |
| 2018-06-30 | 2018-08-08 | $4.37 million | -$4.95 | -$4.77 | -3.77% |
| 2018-03-31 | 2018-06-13 | $3.66 million | -$8.37 | -$5.85 | -43.08% |
| 2017-12-31 | 2018-02-07 | $4.84 million | -$6.57 | -$5.55 | -18.38% |
| 2017-09-30 | 2017-11-09 | $4.33 million | -$6.03 | -$6.21 | 2.9% |
| 2017-06-30 | 2017-08-08 | $3.84 million | -$7.38 | -$6.57 | -12.33% |
| 2017-03-31 | 2017-06-05 | $4.03 million | -$5.13 | -$6.03 | 14.93% |
| 2016-12-31 | 2017-02-09 | $3.36 million | $34.56 | $27.72 | 24.68% |
| 2016-09-30 | 2016-11-10 | $2.8 million | -$4.14 | -$5.31 | 22.03% |
| 2016-06-30 | 2016-07-28 | $2.64 million | -$5.49 | -$4.95 | -10.91% |
| 2016-03-31 | 2016-06-16 | $2.58 million | -$7.20 | -$4.05 | -77.78% |
| 2015-12-31 | 2016-02-04 | $2.48 million | -$8.55 | -$4.05 | -111.11% |
| 2015-09-30 | 2015-11-05 | $631000 | -$0.55 | -$0.55 | 0% |
| 2015-06-30 | 2015-07-30 | $3.68 million | -$0.75 | -$0.47 | -59.57% |
| 2015-03-31 | 2015-06-11 | $3.98 million | $1.20 | -$1.25 | 196% |
| 2014-12-31 | 2015-02-12 | $3.22 million | -$3.45 | -$0.90 | -283.33% |
| 2014-09-30 | 2014-11-13 | $3.26 million | -$0.40 | -$0.90 | 55.56% |
| 2014-06-30 | 2014-08-07 | $3.39 million | -$8.55 | -$7.65 | -11.76% |
| 2014-03-31 | 2014-06-12 | $2.91 million | -$12.60 | -$9.22 | -36.66% |
| 2013-12-31 | 2014-02-13 | $3.29 million | -$12.60 | -$6.75 | -86.67% |
| 2013-09-30 | 2013-11-19 | $4.09 million | -$2.25 | -$6.75 | 66.67% |
| 2013-06-30 | 2013-08-08 | $3.37 million | -$6.30 | -$11.70 | 46.15% |
| 2013-03-31 | 2013-06-13 | $3.34 million | -$10.35 | -$6.00 | -72.5% |
| 2012-12-31 | 2013-02-13 | $3.54 million | -$9.45 | -$23.62 | 59.99% |
| 2012-09-30 | 2012-11-01 | $4.53 million | -$15.75 | $9.45 | -266.67% |
| 2012-06-30 | 2012-08-02 | $4.05 million | -$15.75 | -$15.75 | 0% |
| 2012-03-31 | 2012-06-07 | $3.35 million | -$15.75 | -$23.62 | 33.32% |
| 2011-12-31 | 2012-02-02 | $2.79 million | -$28.35 | -$14.70 | -92.86% |
| 2011-09-30 | 2011-11-03 | $3.66 million | -$9.45 | -$16.80 | 43.75% |
| 2011-06-30 | 2011-08-04 | $2.94 million | -$25.20 | -$18.90 | -33.33% |
| 2011-03-31 | 2011-06-02 | $2.71 million | -$15.75 | -$23.10 | 31.82% |
| 2010-12-31 | 2011-02-03 | $2.31 million | -$25.20 | -$21.00 | -20% |
| 2010-09-30 | 2010-11-04 | $2.47 million | -$18.90 | -$26.77 | 29.4% |
| 2010-06-30 | 2010-08-05 | $2.26 million | -$28.35 | -$22.05 | -28.57% |
| 2010-03-31 | 2010-06-04 | $2.23 million | -$18.15 | ||
| 2009-12-31 | 2010-02-04 | $1.61 million | -$25.20 | -$22.05 | -14.29% |
| 2009-09-30 | 2009-11-05 | $1.67 million | -$31.50 | -$31.50 | 0% |
| 2009-06-30 | 2009-08-07 | $1.85 million | -$57.53 | ||
| 2009-03-31 | 2009-06-12 | $1.48 million | -$37.80 | ||
| 2008-12-31 | 2009-02-13 | $1.22 million | -$65.67 | ||
| 2008-09-30 | 2008-11-06 | $1.48 million | -$135.45 | -$126.00 | -7.5% |
| 2008-06-30 | 2008-08-05 | $1.21 million | -$103.95 | -$102.90 | -1.02% |
| 2008-03-31 | 2008-06-11 | $926000 | -$107.10 | -$124.43 | 13.93% |
| 2007-12-31 | 2008-02-07 | $1.07 million | -$126.00 | -$135.45 | 6.98% |
| 2007-09-30 | 2007-11-12 | $977000 | -$138.60 | -$141.75 | 2.22% |
| 2007-06-30 | 2007-08-09 | $866000 | -$132.30 | -$148.05 | 10.64% |
| 2007-03-31 | 2007-06-07 | $1.16 million | -$166.95 | -$129.15 | -29.27% |
| 2006-12-31 | 2007-02-22 | $1.05 million | -$369.08 |
Sonoma Pharmaceuticals, Inc (SNOA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 33000 | -85000 | N/A | N/A | 248000 |
| Income Before Tax | -136000 | 228000 | N/A | N/A | -1.08 million |
| Selling General Administrative | 2.1 million | 2.42 million | N/A | N/A | 2.89 million |
| Gross Profit | 2 million | 2.5 million | N/A | N/A | 2.16 million |
| Ebit | -131000 | 232000 | N/A | N/A | -982000 |
| Operating Income | -138000 | 169000 | N/A | N/A | -982000 |
| Income Tax Expense | N/A | N/A | N/A | 121000 | N/A |
| Total Revenue | 4.94 million | 5.77 million | N/A | N/A | 4.68 million |
| Cost of Revenue | 2.94 million | 3.27 million | N/A | N/A | 2.52 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -102000 |
| Net Income From Continuing Operations | -626000 | 151000 | N/A | N/A | -1.08 million |
| Net Income Applicable to Common Shares | -650000 | 120000 | 993000 | -1.37 million | -1.08 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -992000 | 1.56 million | -778000 | -183000 | 785000 |
| Total Cash Flow from Investing Activities | -79000 | 554000 | 3.68 million | 33000 | -57000 |
| Net Borrowings | -216000 | 1.09 million | N/A | -106000 | -105000 |
| Total Cash Flow from Financial Activities | 213000 | N/A | N/A | 1.27 million | -105000 |
| Change to Operating Activities | N/A | -1.41 million | -77000 | 103000 | -402000 |
| Change in Cash | -232000 | N/A | N/A | 495000 | -1.05 million |
| Total Cash from Operating Activities | -366000 | -2.28 million | -3.59 million | -840000 | -898000 |
| Depreciation | 54000 | N/A | N/A | 68000 | 68000 |
| Other Cash Flow from Investing Activities | -34000 | -4000 | 3.8 million | 42000 | 8000 |
| Change to Inventory | 559000 | N/A | N/A | 367000 | 190000 |
| Change to Account Receivables | N/A | N/A | N/A | -223000 | -469000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 262000 | -809000 | -935000 | 112000 | 133000 |
| Capital Expenditures | 45000 | N/A | N/A | 9000 | 65000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 5.92 million | 6.58 million | N/A | N/A | 5.29 million |
| Total Stockholder Equity | 12.32 million | 11.56 million | N/A | N/A | 11.21 million |
| Other Current Liabilities | 404000 | 386000 | N/A | N/A | 285000 |
| Total Assets | 18.23 million | 18.15 million | N/A | N/A | 16.5 million |
| Common Stock | 2000 | 2000 | 2000 | 2000 | 2000 |
| Other Current Assets | 3.31 million | 2.96 million | N/A | N/A | N/A |
| Retained Earnings | -172.54 million | -171.89 million | -171.25 million | -172.25 million | -170.87 million |
| Other Liabilities | N/A | N/A | 240000 | 245000 | 322000 |
| Other Assets | N/A | N/A | 848000 | 850000 | 1.1 million |
| Cash | 5.54 million | 4.32 million | N/A | N/A | 3.73 million |
| Total Current Liabilities | 3.88 million | 4.57 million | N/A | N/A | 4.16 million |
| Other Stockholder Equity | -4.24 million | -5.26 million | -5.45 million | -5.61 million | -4.18 million |
| Property, Plant & Equipment | 404000 | 370000 | 715000 | 1.33 million | 1.54 million |
| Total Current Assets | 16.21 million | 16.27 million | N/A | N/A | 13.86 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 12.32 million | 11.56 million | 11.41 million | 8.71 million | 11.21 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 1.31 million | 1.31 million | N/A | N/A | N/A |
| Inventory | 2.96 million | 3.7 million | N/A | N/A | 2.83 million |
| Accounts Payable | 3.48 million | 4.13 million | N/A | N/A | 2.16 million |
Sonoma Pharmaceuticals, Inc (SNOA) Chart:
Sonoma Pharmaceuticals, Inc (SNOA) News:
Below you will find a list of latest news for Sonoma Pharmaceuticals, Inc (SNOA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sonoma Pharmaceuticals, Inc (SNOA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest SNOA Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:56 PM EST | 100 | $3.11 |
| Jun 13, 2022 7:56 PM EST | 12 | $3.11 |
| Jun 13, 2022 7:56 PM EST | 100 | $3.11 |
| Jun 13, 2022 7:56 PM EST | 100 | $3.11 |
| Jun 13, 2022 7:59 PM EST | 22 | $3.09 |
Sonoma Pharmaceuticals, Inc (SNOA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002126/0001683168-20-002126-index.htm |
| 2018-10-23 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1367083/000000000018033206/0000000000-18-033206-index.htm |
| 2018-03-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1367083/000110465918016307/0001104659-18-016307-index.htm |
| 2018-11-05 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1367083/000110465918065970/0001104659-18-065970-index.htm |
| 2018-11-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1367083/000110465918069403/0001104659-18-069403-index.htm |
| 2018-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1367083/000110590718000013/0001105907-18-000013-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1367083/000110590719000003/0001105907-19-000003-index.htm |
| 2020-01-22 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/1367083/000135445720000027/0001354457-20-000027-index.htm |
| 2017-12-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316817003265/0001683168-17-003265-index.htm |
| 2017-12-08 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316817003266/0001683168-17-003266-index.htm |
| 2018-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000036/0001683168-18-000036-index.htm |
| 2018-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000037/0001683168-18-000037-index.htm |
| 2018-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000038/0001683168-18-000038-index.htm |
| 2018-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000039/0001683168-18-000039-index.htm |
| 2018-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000040/0001683168-18-000040-index.htm |
| 2018-02-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000339/0001683168-18-000339-index.htm |
| 2018-02-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000424/0001683168-18-000424-index.htm |
| 2018-03-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000552/0001683168-18-000552-index.htm |
| 2018-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000569/0001683168-18-000569-index.htm |
| 2018-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000571/0001683168-18-000571-index.htm |
| 2018-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000573/0001683168-18-000573-index.htm |
| 2018-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000575/0001683168-18-000575-index.htm |
| 2018-03-05 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000591/0001683168-18-000591-index.htm |
| 2018-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000600/0001683168-18-000600-index.htm |
| 2018-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000628/0001683168-18-000628-index.htm |
| 2018-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000658/0001683168-18-000658-index.htm |
| 2018-03-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000672/0001683168-18-000672-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001578/0001683168-18-001578-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001579/0001683168-18-001579-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001580/0001683168-18-001580-index.htm |
| 2018-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001589/0001683168-18-001589-index.htm |
| 2018-06-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001675/0001683168-18-001675-index.htm |
| 2018-06-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001786/0001683168-18-001786-index.htm |
| 2018-07-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001973/0001683168-18-001973-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002012/0001683168-18-002012-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002014/0001683168-18-002014-index.htm |
| 2018-07-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002045/0001683168-18-002045-index.htm |
| 2018-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002195/0001683168-18-002195-index.htm |
| 2018-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002211/0001683168-18-002211-index.htm |
| 2018-09-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002728/0001683168-18-002728-index.htm |
| 2018-09-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002794/0001683168-18-002794-index.htm |
| 2018-09-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002816/0001683168-18-002816-index.htm |
| 2018-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818002956/0001683168-18-002956-index.htm |
| 2018-10-12 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/0001683168-18-003037-index.htm |
| 2018-11-07 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003262/0001683168-18-003262-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003305/0001683168-18-003305-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003307/0001683168-18-003307-index.htm |
| 2018-11-16 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003469/0001683168-18-003469-index.htm |
| 2018-11-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003470/0001683168-18-003470-index.htm |
| 2018-11-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003471/0001683168-18-003471-index.htm |
| 2018-11-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003517/0001683168-18-003517-index.htm |
| 2018-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003538/0001683168-18-003538-index.htm |
| 2018-11-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003574/0001683168-18-003574-index.htm |
| 2018-12-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003715/0001683168-18-003715-index.htm |
| 2018-12-19 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003749/0001683168-18-003749-index.htm |
| 2018-12-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316818003784/0001683168-18-003784-index.htm |
| 2019-01-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819000036/0001683168-19-000036-index.htm |
| 2019-01-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316819000083/0001683168-19-000083-index.htm |
| 2019-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316819000117/0001683168-19-000117-index.htm |
| 2019-01-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316819000118/0001683168-19-000118-index.htm |
| 2019-02-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316819000401/0001683168-19-000401-index.htm |
| 2019-04-12 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001013/0001683168-19-001013-index.htm |
| 2019-04-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001147/0001683168-19-001147-index.htm |
| 2019-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001691/0001683168-19-001691-index.htm |
| 2019-05-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001765/0001683168-19-001765-index.htm |
| 2019-05-31 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001766/0001683168-19-001766-index.htm |
| 2019-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001872/0001683168-19-001872-index.htm |
| 2019-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819001947/0001683168-19-001947-index.htm |
| 2019-07-01 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1367083/000168316819002069/0001683168-19-002069-index.htm |
| 2019-07-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1367083/000168316819002371/0001683168-19-002371-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316819002573/0001683168-19-002573-index.htm |
| 2019-09-18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1367083/000168316819002961/0001683168-19-002961-index.htm |
| 2019-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003115/0001683168-19-003115-index.htm |
| 2019-10-03 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003149/0001683168-19-003149-index.htm |
| 2019-10-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003203/0001683168-19-003203-index.htm |
| 2019-10-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003254/0001683168-19-003254-index.htm |
| 2019-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003256/0001683168-19-003256-index.htm |
| 2019-10-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003272/0001683168-19-003272-index.htm |
| 2019-10-18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003294/0001683168-19-003294-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003457/0001683168-19-003457-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003642/0001683168-19-003642-index.htm |
| 2019-11-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003817/0001683168-19-003817-index.htm |
| 2019-11-27 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003829/0001683168-19-003829-index.htm |
| 2019-11-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819003854/0001683168-19-003854-index.htm |
| 2019-12-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1367083/000168316819004063/0001683168-19-004063-index.htm |
| 2019-12-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316819004109/0001683168-19-004109-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316820000019/0001683168-20-000019-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316820000020/0001683168-20-000020-index.htm |
| 2020-02-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316820000514/0001683168-20-000514-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820000599/0001683168-20-000599-index.htm |
| 2020-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001229/0001683168-20-001229-index.htm |
| 2020-04-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001266/0001683168-20-001266-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001272/0001683168-20-001272-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001273/0001683168-20-001273-index.htm |
| 2020-05-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001386/0001683168-20-001386-index.htm |
| 2020-05-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001735/0001683168-20-001735-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001864/0001683168-20-001864-index.htm |
| 2020-06-29 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002120/0001683168-20-002120-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002126/0001683168-20-002126-index.htm |
| 2020-07-10 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002234/0001683168-20-002234-index.htm |
| 2020-07-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002411/0001683168-20-002411-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002539/0001683168-20-002539-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1367083/000168316820002761/0001683168-20-002761-index.htm |
| 2020-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820003109/0001683168-20-003109-index.htm |
| 2020-09-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1367083/000168316820003110/0001683168-20-003110-index.htm |
| 2020-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1367083/000168316820003202/0001683168-20-003202-index.htm |
| 2018-11-16 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1367083/999999999518002915/9999999995-18-002915-index.htm |
| 2018-10-22 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1367083/999999999718008765/9999999997-18-008765-index.htm |
Sonoma Pharmaceuticals, Inc (SNOA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sonoma Pharmaceuticals, Inc (SNOA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 107%Institutional Ownership: 949%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-03-09 | Robert E Miller | Chief Financial Officer | Buy | 1,200.00 | 3.90 | 4,680.00 | 15,268.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000658/0001683168-18-000658-index.htm |
| 2018-03-12 | Robert E Miller | Chief Financial Officer | Buy | 1,200.00 | 4.03 | 4,836.00 | 16,468.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000658/0001683168-18-000658-index.htm |
| 2018-03-12 | Robert E Miller | Chief Financial Officer | Buy | 1,200.00 | 4.03 | 4,836.00 | 17,668.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000672/0001683168-18-000672-index.htm |
| 2018-03-13 | Robert E Miller | Chief Financial Officer | Buy | 1,200.00 | 4.10 | 4,919.52 | 18,868.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000672/0001683168-18-000672-index.htm |
| 2020-04-23 | Robert Grant Edwards | Chief Financial Officer | Buy | 2,609.00 | 2,609.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001273/0001683168-20-001273-index.htm | ||
| 2020-04-23 | Poggetto John Dal | Chief Financial Officer | Buy | 3,086.00 | 3,201.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316820001272/0001683168-20-001272-index.htm | ||
| 2018-01-02 | James J Schutz | Chief Executive Officer | Buy | 17,211.00 | 33,385.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000040/0001683168-18-000040-index.htm | ||
| 2018-03-08 | James J Schutz | Chief Executive Officer | Buy | 2,473.00 | 3.99 | 9,867.27 | 35,858.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000628/0001683168-18-000628-index.htm |
| 2018-01-02 | SHARON SURREY BARBARI | Director | Buy | 17,211.00 | 41,993.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000036/0001683168-18-000036-index.htm | ||
| 2018-01-02 | Russell Joseph Harrison | Director | Buy | 17,211.00 | 43,291.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000038/0001683168-18-000038-index.htm | ||
| 2018-03-01 | SHARON SURREY BARBARI | Director | Buy | 1,424.00 | 43,417.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000575/0001683168-18-000575-index.htm | ||
| 2018-03-01 | Russell Joseph Harrison | Director | Buy | 1,691.00 | 44,982.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000571/0001683168-18-000571-index.htm | ||
| 2018-01-02 | JOHN MCLAUGHLIN | Director | Buy | 17,211.00 | 44,989.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000039/0001683168-18-000039-index.htm | ||
| 2018-05-30 | Russell Joseph Harrison | Director | Buy | 1,538.00 | 46,520.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001579/0001683168-18-001579-index.htm | ||
| 2018-03-01 | JOHN MCLAUGHLIN | Director | Buy | 1,958.00 | 46,947.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000569/0001683168-18-000569-index.htm | ||
| 2018-05-30 | JOHN MCLAUGHLIN | Director | Buy | 1,781.00 | 48,728.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001580/0001683168-18-001580-index.htm | ||
| 2018-01-02 | Jay E Birnbaum | Director | Buy | 25,817.00 | 49,450.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000037/0001683168-18-000037-index.htm | ||
| 2018-03-01 | Jay E Birnbaum | Director | Buy | 1,157.00 | 50,607.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818000573/0001683168-18-000573-index.htm | ||
| 2018-05-30 | Jay E Birnbaum | Director | Buy | 1,052.00 | 51,659.00 | https://www.sec.gov/Archives/edgar/data/1367083/000168316818001578/0001683168-18-001578-index.htm |